pharma · Clostridium Difficile Infection · Clostridium Difficile Infection Recurrence · ACXP
Acurx Pharmaceuticals
Acurx Pharmaceuticals patent portfolio — 28 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Palatine, USA
- Founded
- 2003
- Employees
- 9
- Programs
- 2
- Drugs
- 1
- Patents
- 28
Acurx Pharmaceuticals patents
28 pharmaceutical patents indexed for Acurx Pharmaceuticals. 1 expire within 24 months.
Acurx Pharmaceuticals has 28 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 1 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12036225
Use of ibezapolstat to promote microbiome health
granted -
US 11857629
Methods and compositions for self-regulated release of active pharmaceutical ingredient
granted -
US 11723885
Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
granted -
US 11554114
Methods and compositions for self-regulated release of active pharmaceutical ingredients
granted -
US 11197837
Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
granted -
US 11103581
Methods and compositions for self-regulated release of active pharmaceutical ingredient
granted -
US 11083794
Methods and compositions for self-regulated release of active pharmaceutical ingredient
granted -
US 11001592
DNA polymerase IIIC inhibitors and use thereof
granted -
US 10836772
DNA polymerase IIIC inhibitors and use thereof
granted -
US 10723741
DNA polymerase IIIC inhibitors and use thereof
granted -
US 10688184
Methods and compositions for self-regulated release of active pharmaceutical ingredient
granted -
US 10610497
Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
granted -
US 10155044
Methods and compositions for deterring abuse
granted -
US 10004699
Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
granted -
US 9757466
Methods and compositions for deterring abuse
granted -
US 9662393
Methods and compositions for self-regulated release of active pharmaceutical ingredient
granted -
US 9492443
Abuse deterrent compositions and methods of making same
granted -
US 9320796
Methods and compositions for self-regulated release of active pharmaceutical ingredient
granted -
US 9101636
Methods and compositions for self-regulated release of active pharmaceutical ingredient
granted -
US 8901113
Methods and compositions for deterring abuse
granted -
US 8822489
Abuse deterrent compositions and methods of making same
granted -
US 8637540
Compositions for deterring abuse of opioid containing dosage forms
granted -
US 8409616
Extended release opioid abuse deterrent compositions and methods of making same
granted -
US 8101630
Extended release opioid abuse deterrent compositions and methods of making same
granted -
US 7981439
Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof
granted -
US 7510726
Methods and compositions for deterring abuse of opioid containing dosage forms
granted -
US 7476402
Methods and compositions for deterring abuse of opioid containing dosage forms
granted -
US 7201920
Methods and compositions for deterring abuse of opioid containing dosage forms
granted
Frequently asked questions
How many patents does Acurx Pharmaceuticals have?
28 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Acurx Pharmaceuticals patents expire?
1 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.